Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Tanswell

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Proceedings of the Royal Society of London. Series B, Biological Sciences|November 5, 1974
The internal structure of the chromaffin granuleA Daniels, A Korda, P Tanswell, et al.
Thrombosis and Haemostasis|August 20, 1986
Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteersM Verstraete, C A Su, P Tanswell, et al.
Clinical Pharmacology and Therapeutics|August 1, 1989
Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjectsP Tanswell, E Seifried, P C Su, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|February 1, 1992
Studies on the functionality of fibrinogen during rt-PA therapy: results of three different methods of fibrinogen determinationE Seifried, M Oethinger, P Tanswell, et al.
European Journal of Clinical Pharmacology|January 1, 1990
Absolute bioavailability of pirenzepine in intensive care patientsP Tanswell, F Hofgärtner, G Bozler, et al.
European Journal of Clinical Pharmacology|January 1, 1989
Steady-state intravenous pharmacokinetics of pirenzepine in patients with hepatic insufficiency and combined renal- and hepatic insufficiencyB Krakamp, P Tanswell, P Leidig, et al.
Thrombosis and Haemostasis|April 1, 1993
Influence of acute myocardial infarction and rt-PA therapy on circulating fibrinogenE Seifried, M Oethinger, P Tanswell, et al.
Klinische Wochenschrift|January 1, 1988
[Recombinant tissue-type plasminogen activator: pharmacokinetics and effect on the hemostasis system of the human]E Seifried, F Böck, P Tanswell, et al.
Lancet (London, England)|August 8, 1987
Fibrin degradation products are not specific markers for thrombolysis in myocardial infarctionE Seifried, P Tanswell, D C Rijken, et al.
Therapeutic Drug Monitoring|June 1, 1987
A selective radioimmunoassay for the determination of pirenzepine in plasma and urineC A Homon, H J Esber, P Zavorskas, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Proceedings of the Royal Society of London. Series B, Biological Sciences|November 5, 1974
The internal structure of the chromaffin granuleA Daniels, A Korda, P Tanswell, et al.
Thrombosis and Haemostasis|August 20, 1986
Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteersM Verstraete, C A Su, P Tanswell, et al.
Clinical Pharmacology and Therapeutics|August 1, 1989
Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjectsP Tanswell, E Seifried, P C Su, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|February 1, 1992
Studies on the functionality of fibrinogen during rt-PA therapy: results of three different methods of fibrinogen determinationE Seifried, M Oethinger, P Tanswell, et al.
European Journal of Clinical Pharmacology|January 1, 1990
Absolute bioavailability of pirenzepine in intensive care patientsP Tanswell, F Hofgärtner, G Bozler, et al.
European Journal of Clinical Pharmacology|January 1, 1989
Steady-state intravenous pharmacokinetics of pirenzepine in patients with hepatic insufficiency and combined renal- and hepatic insufficiencyB Krakamp, P Tanswell, P Leidig, et al.
Thrombosis and Haemostasis|April 1, 1993
Influence of acute myocardial infarction and rt-PA therapy on circulating fibrinogenE Seifried, M Oethinger, P Tanswell, et al.
Klinische Wochenschrift|January 1, 1988
[Recombinant tissue-type plasminogen activator: pharmacokinetics and effect on the hemostasis system of the human]E Seifried, F Böck, P Tanswell, et al.
Lancet (London, England)|August 8, 1987
Fibrin degradation products are not specific markers for thrombolysis in myocardial infarctionE Seifried, P Tanswell, D C Rijken, et al.
Therapeutic Drug Monitoring|June 1, 1987
A selective radioimmunoassay for the determination of pirenzepine in plasma and urineC A Homon, H J Esber, P Zavorskas, et al.
Pageof 4